Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4582736 | 0.81 | KMT2A (0.44) | ALDH1A1CYP1A2ALOX15NFKB1CYP2C19 | |
| SCHEMBL7898821 | 0.80 | HTR3E (0.50) | ALDH1A1CYP3A4CYP1A2MAPK1ABCC9 | |
| SCHEMBL6213539 | 0.78 | ALDH1A1 (0.64) | PLGALDH1A1CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL6213542 | 0.78 | ALDH1A1 (0.64) | PLGALDH1A1CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL6953869 | 0.77 | SMN1; SMN2 (0.38) | ALDH1A1KMT2AUSP2SMN1; SMN2 | |
| SCHEMBL6953872 | 0.77 | SMN1; SMN2 (0.38) | ALDH1A1KMT2AUSP2SMN1; SMN2 | |
| SCHEMBL24872316 | 0.75 | CYP3A4 (0.44) | PLGALDH1A1CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL7978023 | 0.74 | SMN1; SMN2 (0.57) | PLGALDH1A1CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL1309528 | 0.74 | SMN1; SMN2 (0.57) | PLGALDH1A1CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL8916683 | 0.71 | KCNJ11 (0.32) | KCNJ11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120264755-A1 | PYRIDINYL DERIVATIVES AS INHIBITORS OF ENZYME NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | TopoTarget (DE) | 2012-10-18 | — | — | US | disclosed |
| US-6646129-B2 | Treatment of psoriasis and skin cancer | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2003-11-11 | — | — | US | disclosed |
| EP-0984938-B1 | CYANOGUANIDINES AS CELL PROLIFERATION INHIBITORS | LEO PHARMA AS WITH SECONDARY N (DK) | 2003-09-10 | — | — | EP | disclosed |
| EP-0984936-B1 | CYANOGUANIDINES AS CELL PROLIFERATION INHIBITORS | LEO PHARMA AS WITH SECONDARY N (DK) | 2003-09-03 | — | — | EP | disclosed |
| US-20020107400-A1 | Cyanoguanidines as cell proliferation inhibitors | LEO PHARMACEUTICAL PRODUCTS LTD. A/S | 2002-08-08 | — | — | US | disclosed |
| US-6346520-B1 | ANTITUMOR AND ANTICARCINOGENIC AGENTS; PSORIASIS | LEO PHARMACEUTICAL PRODUCTS, LTD. A/S (DK) | 2002-02-12 | — | — | US | disclosed |
| US-6346541-B1 | ANTITUMOR AND ANTICARCINOGENIC AGENTS FOR BREAST, LUNG, AND SKIN CANCER | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2002-02-12 | — | — | US | disclosed |
| US-6300345-B1 | AS ANTIPROLIFERATIVE AGENT | Leo Pharmacuetical Products Ltd. A/S (Løvens kemiske Fabrik Produktionsaktieselskab) (DK) | 2001-10-09 | — | — | US | disclosed |
| US-6197797-B1 | ANTICANCER AGENTS; SKIN DISORDERS | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 2001-03-06 | — | — | US | disclosed |
| US-6121297-A | SUCH AS N-CYANO-N'-(11-PHENOXYUNDECYL)-N?-4-PYRIDYLGUANIDINE; N-CYANO-N'-(10-PHENOXYDECYL)-N?-4-PYRIDYLGUANIDINE; N-CYANO-N'-(9-PHENOXYNONYL)-N?-4-PYRIDYLGUANIDINE; OR THEIR SALTS; TREATING SKIN CANCER | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2000-09-19 | — | — | US | disclosed |
| EP-0984939-A1 | CYANOGUANIDINES AS CELL PROLIFERATION INHIBITORS | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2000-03-15 | — | — | EP | disclosed |
| EP-0984936-A1 | CYANOGUANIDINES AS CELL PROLIFERATION INHIBITORS | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2000-03-15 | — | — | EP | disclosed |
| WO-1998054145-A1 | CYANOGUANIDINES AS CELL PROLIFERATION INHIBITORS | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 1998-12-03 | — | — | WO | disclosed |
| WO-1998054141-A1 | CYANOGUANIDINES AS CELL PROLIFERATION INHIBITORS | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 1998-12-03 | — | — | WO | disclosed |
| US-5696140-A | FOR TREATMENT OF ASTHMA, ALLERGIES, NERVOUS SYSTEM DISORDERS OR CANCER | LEO PHARMACEUTICAL PRODUCTS LTD. (DK) | 1997-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264755-A1 | PYRIDINYL DERIVATIVES AS INHIBITORS OF ENZYME NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | NAMPT, NAPRT, NNT | PLG 2228/4885ALDH1A1 900/4885CYP3A4 1156/4885 |
| US-20020107400-A1 | Cyanoguanidines as cell proliferation inhibitors | CCNC, MKI67, CCNI | PLG 1351/4885ALDH1A1 2883/4885CYP3A4 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.